PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-116.92%
Negative EBIT growth while AVXL is at 12.37%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-185.87%
Negative operating income growth while AVXL is at 12.37%. Joel Greenblatt would press for urgent turnaround measures.
-92.79%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-3998.91%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-3998.91%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-95.29%
Share reduction while AVXL is at 3.70%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-95.29%
Reduced diluted shares while AVXL is at 3.70%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
75.47%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
66.24%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-141.36%
Negative 10Y OCF/share CAGR while AVXL stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-420.27%
Negative 5Y OCF/share CAGR while AVXL is at 20.34%. Joel Greenblatt would question the firm’s operational model or cost structure.
-362.87%
Negative 3Y OCF/share CAGR while AVXL stands at 85.64%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-427041.90%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-659606.65%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-1088784.48%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
-4964.64%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-1566.95%
Negative 3Y equity/share growth while AVXL is at 42.28%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1993307.75%
Positive asset growth while AVXL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
57821.37%
BV/share growth above 1.5x AVXL's 27.63%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
2.24%
We have some new debt while AVXL reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
178.96%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
203.49%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.